Kornimate/medical-research-clean huggingface dataset:
investigation of the effects of selective exercise training in multiple sclerosis

Conditions: Multiple Sclerosis; Exercise

Summary: selective exercise programs specific to muscle groups, with the workload to be done in line with the muscle's own structure, can enable more strength to be released with less fatigue in ms, and this increase in strength can increase balance and functional activities. to determine the effects of type training (selective exercise training), eccentric and concentric training on function, balance, fatigue and muscle architecture.

recovery and enhancement of muscle function in ms is one of the main goals in physiotherapy and rehabilitation. in literature studies, it is stated that eccentric and concentric exercises are effective exercise approaches in increasing strength and reducing fatigue. however, the best exercise method is not yet clear in terms of providing better performance adaptation with less fatigue. considering the architectural features of the lower extremity muscles, it is aimed to increase the angle of pennation with programs that include concentric strengthening of the quadriceps, gastro-soleus and gastrocnemius muscles, which are suitable muscle groups to produce large forces by design. with programs that include eccentric strengthening of the hamstring and tibialis anterior muscles that function in a wide range of motion and have high excursion ability, it is aimed to increase fiber length.

Eligibility criteria:
inclusion criteria: * between the ages of 18-50, * with an extended disability status scale (edss) score of 4 or less, * no regular exercise habit * able to walk on the treadmill, * no pregnancy, * not receiving corticosteroid treatment in the last month, * fampridine etc. in the last 1 month. not taking medication, * patients who have not received botox treatment in the last 6 months exclusion criteria: patients who do not agree to volunteer

Keywords: multiple sclerosis muscle architecture eccentric exercise concentric exercise
the impact of right ventricular pacing on tricuspid regurgitation

Conditions: Tricuspid Regurgitation

Summary: "1" to examine whether right ventricular pacing has an impact on tricuspid regurgitation grade that is related to pacing rather than to valve closure interference by the electrode.

"1" traditionally, tricuspid regurgitation in the presence of pacemaker is attributed to the physical interference of the valve closure by the electrode. "2" right ventricular pacing may be associated with dyssynchrony in contraction of the right ventricular wall (i.e. septum and free wall. "3" the tricuspid sub-valvar apparatus is anchored to the septum and free wall, thus may be sensitive to dyssynchrony in those wals contraction. "4" the study hypothesis is that the dyssynchrony in right ventricular contraction, induced by pacing, may increase tricuspid regurgitation grade and that this is a mechanism is independent of the mechanical effect of the electrode on the valve closure.

Eligibility criteria:
inclusion criteria: * age \>18 years * permanent pacemaker exclusion criteria: * epicardial pacing * left ventricular dysfunction * organic tricuspid regurgitation * bi-ventricular pacemaker * atrial fibrillation * complete pacemaker dependence

Keywords: pacemaker tricuspid regurgitation
a clinical study of b001 injection in the treatment of neuromyelitis optica spectrum disorders(nmosd)

Conditions: Neuromyelitis Optica Spectrum Disorders

Summary: to evaluate the efficacy and safety of b001 injection in aquaporin-4 antibody positive patients with neuromyelitis optica spectrum disorder.


Eligibility criteria:
inclusion criteria: 1. confirmed nmosd patients; 2. experienced at least 1 recurrence of nmosd within 1 year or at least 2 recurrence within 2 years prior to screening; 3. the blood pregnancy tests were negative within 7 days before the first dose in fertile female subjects. the fertile subjects and the male subjects whose partner are fertile woman agree to use reliable contraception during the study period and within 6 months after the study drug discontinuation; 4. volunteer to participate in clinical research; fully understand and know the study and sign the informed consent; willing to follow and able to complete all test procedures. exclusion criteria: 1. subjects with severe nmosd were judged by the researcher to be unfit to participate in this study; 2. subjects with chronic active immune system diseases undergoing systematic treatment; 3. received anti-cd20 or other cell depletion therapy within 6 months before first dose; 4. received the prescribed drug treatment at the prescribed time before first dose; 5. subjects who have participated in any drug clinical trials within 28 days prior to the first dose; 6. received hematopoietic stem cell transplantation、 lymphatic irradiation before first dose; 7. pregnant or lactating women; subjects with birth plans during the trial; 8. subjects who had undergone major surgery within 2 months prior to screening or were scheduled to undergo major surgery during the trial; 9. subjects with severe, progressive, or uncontrolled disease who have been assessed by the investigator to be at increased risk of participating in the study; 10. a history of gastrointestinal perforation and/or fistula within 6 months prior to screening; 11. subjects who received a live or attenuated vaccine within 4 weeks prior to initial administration, or who plan to receive vaccination during the study period; 12. subjects with severe or persistent infection currently or within the 1 months prior to screening; 13. subjects with positive gamma interferon release test; 14. subjects who currently have active hepatitis or have a history of severe liver disease; 15. uncontrolled systemic disease, or any other reason the investigator deems inappropriate for inclusion; 16. abnormal laboratory test results; 17. subjects with a history of alcohol or drug abuse in the 6 months prior to screeing, or who are abusing; 18. subjects with symptoms of severe mental illness who are clinically uncooperative; 19. subjects who were unable to undergo magnetic resonance imaging during the study and who had other conditions that the investigator considered inappropriate to enroll.
salvage surgery following downstaging of advanced non-small cell lung cancer by targeted therapy (sdant)

Conditions: Non Small Cell Lung Cancer

Summary: the purpose of this study is to evaluate the safety and efficacy of neoadjuvant targeted therapy followed by surgery in participants with advanced non-small cell lung cancer.

advanced non-small cell lung cancer (nsclc) accounts for a high proportion of lung cancer cases. targeted therapy improve the survival in these patients, but acquired drug resistance will inevitably occur. if tumor downstaging is achieved after targeted therapy, could surgical resection before drug resistance improve clinical benefits for patients with advanced nsclc? here, the investigators conducted a clinical trial showing that for patients with advanced driver gene mutant nsclc who did not progress after targeted therapy, salvage surgery (ss) could improve progression-free survival (pfs).

Eligibility criteria:
inclusion criteria: * pathological diagnosis of nsclc with confirmed activation of driver gene mutation (egfr mutant: exon 19 deletion or exon 21 l858r mutation; alk-rearrangement) by amplification refractory mutation system (arms); * stage iiib-iv according to the eighth edition of the american joint committee on cancer staging system confirmed by pathological diagnosis and positron emission tomography-computed tomography (pet-ct) and biopsy * written informed consent provided； * age 18-70 when signing the consent form, both male and female; * the ecog score is 0 or 1; * adequate hematological function, liver function and renal function; * female participants should not be pregnant or breast-feeding. exclusion criteria: * previously received systemic anti-tumor therapy for non-small cell lung cancer; * subjects who have received chest radiotherapy in the past; * known human immunodeficiency virus (hiv) infection; * any unstable systemic disease (including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within the previous year, serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic disease); * pregnancy or breast-feeding women; * ingredients mixed with small cell lung cancer patients.

Keywords: unresectable advanced nsclc targeted therapy salvage surgery
effectiveness of the application(app) on individualized antithrombotic therapy

Conditions: Antithrombotic

Summary: develop an exemplary anti-thrombotic therapy network data platform and a intelligent terminal application(app), establish an new pattern used in long-time anti-thrombotic management based on dynamic risk evaluation, and promoted and verified by 10 thousands large sample's cohort study.

1.1.develop and optimize antithrombotic therapy network data platform and thrombotic risk evaluate the intelligent terminal app, establish a new pattern based on dynamic risk evaluation and event-triggered response, settle the conundrum in clinical practice about antithrombotic therapy such as poor compliance, lag and unreasonable in drug adjustment. 1.2.settle the technical problem that intelligent terminal app code isn't compatible with most tablet pcs and smartphones. 1.3.impel the data platform to render and integrate with the daily medical system, enhance its accuracy, compatibility, privacy, and quality standard. 1.4.promote the new pattern of anti-thrombotic management by large sample's cohort study, increase the patients' compliance, reduce the readmission rate and adverse event rate of heart and cerebral vessels.

Eligibility criteria:
inclusion criteria: * age≥18 years; * clinical confirmed coronary heart disease. including definite history of myocardial infarction, stable angina with exercise electrocardiography test(treadmill exercise) positive, unstable angina with electrocardiogram(ecg) ischemic changes or troponin positive, coronary angiography(cag) hints at least one coronary artery stenoses over 50%, post-operative of percutaneous coronary intervention(pci) or coronary artery bypass grafting(cabg); * be receiving anti-thrombotic therapy; * be voluntary to participate in the study., and sign informed consent form. exclusion criteria: * inability to obtain consent from participants; * unable to record the medical data through terminal applications(app)

Keywords: risk evaluation individualized treatment coronary artery disease antithrombotic therapy chinese people application
tablet-aided behavioral intervention effect on self-management skills

Conditions: Diabetes Mellitus, Type 2; Diabetes Mellitus, Adult-Onset; Diabetes Mellitus, Non-Insulin-Dependent; Diabetes Mellitus, Noninsulin Dependent; Diabetes Mellitus, Type II

Summary: the purpose of this project is two-fold: (1) to determine the feasibility of recruiting rural african american (aa) adults in south carolina (sc) for assessing the usefulness of tablet-based resources in good diabetes self-management behaviors, and (2) to test a tablet-aided intervention for improving diabetes self-management behaviors

the proposed study will assess the feasibility of recruitment of african american adults residing in rural south carolina who will assist with improving the usability of tablet computers. in addition, we will implement a pilot trial of the tablets (tablet-aided behavioral intervention effect on self-management skills) intervention for diabetes, using motivational strategies, among rural african americans. the proposed project is designed to address 3 important issues: recruitment for a hard-to-reach population, utility of technology-enabled intervention, and development of a tablet-aided intervention tailored to understand best practices for diabetes self-management

Eligibility criteria:
inclusion criteria: * age ≥45 years * clinical diagnosis of diabetes with hba1c ≥8% and either diagnosis of hyperlipidemia with ldl \>100mg/dl or hypertension with bp \>140/80mmhg * self-identified as african american * residence in a 4g cellular service area * able to communicate in english exclusion criteria: * cognitive impairment * active alcohol or drug abuse/dependency * acute decompensation of chronic conditions precluding participation * participation in other diabetes clinical trials * a life expectancy \<6 months

Keywords: diabetes mellitus, type 2 diabetes mellitus, adult-onset diabetes mellitus, non-insulin-dependent diabetes mellitus, noninsulin dependent diabetes mellitus, type ii african americans blacks non-hispanic blacks randomized control trial controlled clinical trial behavioral research behavioral medicine
reactiv8 implantable neurostimulation system for chronic low back pain

Conditions: Chronic Low Back Pain

Summary: the purpose of this trial is to evaluate the safety and efficacy of reactiv8 for the treatment of adults with chronic low back pain when used in conjunction with medical management.


Eligibility criteria:
inclusion criteria: 1. age ≥22 years, ≤75 years 2. chronic low back pain that has persisted \>90 days prior to the baseline visit. 3. continuing low back pain despite \>90 days of medical management. 4. qualifying pain score. 5. qualifying disability score. 6. evidence of lumbar multifidus muscle dysfunction. 7. be willing and capable of giving informed consent. 8. ability to comply with the instructions for use and to operate reactiv8, and to comply with this clinical investigation plan. 9. suitable for reactiv8 surgery as determined by the implanting physician prior to inclusion. exclusion criteria: 1. bmi \> 35 2. back pain characteristics: 1. any surgical correction procedure for scoliosis at any time, or a current clinical diagnosis of scoliosis. 2. lumbar spine stenosis, as defined by an anterior-posterior diameter of the spinal canal of \<10mm in subjects with lower extremity pain. 3. neurological deficit possibly associated with the back pain (e.g. foot drop). 4. back pain due to pelvic or visceral reasons (e.g.: endometriosis or fibroids) or infection (e.g.: post herpetic neuralgia). 5. back pain due to inflammation or damage to the spinal cord or adjacent structures (e.g. arachnoiditis or syringomyelia). 6. pathology seen on mri that is clearly identified and is likely the cause of the clbp that is amenable to surgery. 7. back pain due to vascular causes such as aortic aneurysm and dissection. 3. any current indication for back surgery according to local institutional guidelines, or has indication for back surgery but cannot undergo surgery for other reasons. 4. leg pain described as being worse than back pain, or radiculopathy (neuropathic pain) below the knee. 5. source of pain is the sacroiliac joint as determined by the investigator. 6. drug use. 7. surgical and other procedures exclusions. 8. any prior diagnosis of lumbar vertebral compression fracture, lumbar pars fracture, or lumbar annular tear with disc protrusion that is amenable to surgery. 9. planned surgery. 10. co-morbid chronic pain conditions. 11. other clinical conditions. 12. psycho-social exclusions. 13. protocol compliance exclusions. 14. general exclusions.
firm ablation versus pulmonary vein isolation for the treatment of paroxysmal atrial fibrillation (paf)

Conditions: Paroxysmal Atrial Fibrillation

Summary: the study is designed as a prospective, multicenter, single-blind, randomized study to assess the safety and effectiveness of firm-guided radiofrequency (rf) ablation procedures for the treatment of symptomatic paroxysmal atrial fibrillation (paf). the subjects will be blinded to study treatment for the duration of the study period.


Eligibility criteria:
key inclusion criteria: * experiencing at least two (2) documented episodes of paroxysmal atrial fibrillation in the last 3 months preceding study entry with clinical indication for atrial fibrillation (af) ablation per guidelines. at least one episode should be documented by rhythm strip or ecg. * indicated for af ablation according to current european heart rhythm association (ehra) guidelines. * prescribed with oral anticoagulation therapy, in indicated patients per the latest ehra guidelines. * willingness and able to remain on anti-coagulation therapy as per the latest ehra guidelines. * left atrial diameter \< 5.5 cm as measured and image ((computed tomography (ct)/ transesophageal echocardiogram (tee)/ transthoracic echocardiogram (tte)/ magnetic resonance imaging (mri) or intracardiac echocardiography (ice)) documented within previous six months up to pre-procedure. * sustained af (\>5 min uninterrupted) during the electrophysiology procedure. if the subject is not experiencing spontaneous, sustained af, it may be induced by burst pacing (typically from the coronary sinus) with or without isoproterenol infusion in conventional clinical fashion. key exclusion criteria: * new york heart association heart failure (nyha) class iii - iv. * ejection fraction \< 40% (within previous six months). * history of myocardial infarction (mi) within the past three months. * any concomitant arrhythmia or therapy that could interfere with the interpretation of the results from this study. * atrial septal defect (asd) closure device, left atrial appendage (laa) closure device, prosthetic mitral or tricuspid valve, or permanent pacemaker. * any previous af catheter ablation. * history of prior cardioversion for af lasting \> 48 hours. * continuous af episode lasting \> 7 days immediately prior to the procedure without a sinus rhythm.
predictive factors of autonomy loss in real-life cohort

Conditions: Memory Disorders

Summary: the alzheimer's disease or related disorders (adrd) are among the most disabling diseases because of their main features such as cognitive impairment, loss of functional autonomy and behavioural disorders. in absence of current curative treatment, the identification of the predictive risk factors of progression of the disease, evaluated through its main symptoms, represents a major stake of public health. the investigators aim at developing a regional database, which includes the patient medical records on a prospective basis, in collaboration with the medical and administrative staff and with the university hospital computer science departments. the main objective is to study the predictive factors associated with change in functional autonomy level, measured every 6 to 12 months in centres across region auvergne rhone-alpes in france. the real-life study population will consist in about 5400 patients with adrd. the inclusion period will be of 3 years, the length of follow-up of each patient will be of 10 years max for a total study length of 13 years.


Eligibility criteria:
inclusion criteria: * patients aged 18 years and older, undergoing a medical visit in a memory center or neuro-cognition service * patients living at home or in housing * patients with memory impairment, at all stage of the disease exclusion criteria: * patients in institution * patients under legal protection * patients with a hearing or visual impairment, which prevents carrying out examinations
human tissue repository for wound care

Conditions: Human Tissue Repository

Summary: the objective of this study is to create a human tissue repository to be used as a resource for future tissue repair research at kci usa, inc.

the study design is a multicenter study involving the collection of human biological specimens in subjects with various wound classifications and types for the purpose of a human tissue repository to be used as a resource for future tissue repair research at kci usa, inc. subjects participating in this study will have a 6mm tissue punch biopsy or equivalent tissue specimen harvested from the healthiest margin of the wound. tissue collection may occur at visits 2, 3, 4 and 5. visit 2 may be combined with screening, visit 1. subjects will have a minimum of one (1) and a maximum of four (4) specimen collection visits. specimens may be collected from one or multiple different tissues (connective tissue, muscle, bone, and dermis) at any or all visits. each specimen will be placed in a separate appropriate vial. necrotic tissue with eschar and bodily fluids such as blood, wound fluid or sputum will not be collected. tissue from healthy, healing wounds will also be accepted. tissue collection visits shall occur at least twenty-four (24) hours apart. ten (10) to twenty-five (25) percent of the sites will be selected to collect all the specimens in cryovials containing a pre-aliquoted amount (1.5ml) of rnalater. ten (10) to twenty-five (25) percent of the sites will be selected to collect all the specimens in cryovials containing a pre-aliquoted amount of hypothermosol. the remaining sites will collect all the specimens in a vial containing no diluents. all samples will be coded by the collection site prior to shipment to kci.

Eligibility criteria:
inclusion criteria: * subject's wound is acute or chronic and classified as one of the following wound types: diabetic, pressure ulcer, burn, traumatic or dehisced, and subject signs the separate informed consent form for the study. the consent process for tissue collection should occur separately from any surgical consent. * subject is reported to be physically and mentally able and willing to comply with the protocol. * subject is between 18 - 75 years old. exclusion criteria: * reported presence of human immunodeficiency virus. * reported presence of acquired immune deficiency syndrome. * reported presence of hepatitis. * reported presence of cancer in the wound. * reported presence or suspected presence of infection (indicated by signs and symptoms of infection such as redness/swelling, or a positive culture, etc.) * presence of untreatable osteomyelitis. * presence of any other severe concurrent disease, which, in the judgment of the investigator, would make the subject inappropriate for entry into the study. * necrotic tissue with eschar present that cannot be debrided. * subject is unwilling or unable to comply with the protocol. * subject is a suspected or known intravenous drug user. * donation of tissue which, in the judgment of the investigator, may pose venous or arterial compromise.

Keywords: human tissue repository
phase ii safety study of 2 dose regimens of hepastem in patients with aclf

Conditions: Acute-On-Chronic Liver Failure

Summary: the study will assess the safety of different dose regimens of hepastem in cirrhotic patients with aclf or with acute decompensation at risk of developing aclf up to day 28 of the active study period.


Eligibility criteria:
main inclusion criteria: * diagnosed cirrhosis * patient with acute decompensation of cirrhosis * serum total bilirubin ≥ 6 mg/dl (≥100 umol/l) * the inr measurement has to be : 1.2 ≤ inr \< 2 main exclusion criteria: * absence of portal vein flow * known or medical history of thrombotic events * gastrointestinal hemorrhage requiring blood transfusion * variceal bading or sclerosis within 4 weeks before infusion * septic shock or non-controlled bacterial infection * clinical evidence of aspergilus infection. * circulatory failure * respiratory disordered * coagulation disorders defined as inr ≥ 2, fibrinogen \< 100 mg/dl or platelets \< 50.000/mm3 * meld score \> 30. * major invasive procedure within 4 weeks before infusion * previous organ transplantation and/or ongoing immunosuppressive treatments. * renal failure due to chronic kidney disease. * clinically significant left-right cardiac shunt.

Keywords: acute-on-chronic liver failure aclf